Advanced search

Search our library

Top 10 mistakes in antibacterial development
Bootcamp: Post-Approval Economics for New Antibiotics (ASM/ESCMID 2019)
Bootcamp: Understanding the Potential for Antimicrobial Resistance in the Drug Discovery Process (ASM/ESCMID 2019)
New initiatives to support AMR innovation (BSAC Spring Conference 2019)
Resistance testing – beyond serial passage experiments
Antimicrobial Chemotherapy Conference 2019
Bootcamp: Preclinical Toxicology (ESCMID/ASM 2018)
Bootcamp: Medicinal Chemistry (ESCMID/ASM 2018)
Coping with Preclinical Toxicology Challenges
Alternatives to (classical) antibiotics: what will it take to convincingly develop a virulence inhibitor or similar indirect agent?
PK-PD in support of accelerated programmes: how much is enough?
US regulatory tools for expedited antibacterial development programmes
EU regulatory tools for expedited antibacterial development programmes
Decisions, Decisions: What Makes a Good Hit? A Good Lead? Why Do You Write a TPP? How Do You Write a TPP?
How Does a Molecule Become a Physical Medicine to be Given to a Human: The Importance of Chemistry, Manufacturing, and Controls
Clinical Microbiology for a Development Program
Saving childrens’ lives – treating neonatal sepsis
Discovery of new antibacterials using artificial intelligence (computational chemoinformatics)
Developing antibiotics for children – medical need and regulatory challenges
Building better breakpoints: data and methods needed to determine breakpoints for new agents
Exploring safety issues in antimicrobial drug development
Moving from preclinical to clinical-stage: Challenges and opportunities
The challenges and opportunities for antimicrobial R&D in low- and middle-income countries – India case study
Clinical development of antimicrobials – Phase 1 development challenges
Putting children first in the fight against antibiotic resistance
GARDP: Bringing new treatments for drug-resistant infections to all who need them
Test tube to patient: PK/PD of fixed dose beta-lactam/beta-lactamase inhibitor combinations
Assay development for measuring antibiotic accumulation in Gram-negative bacteria
Probability of target attainment analyses for dose selection in antimicrobial drug development
Inhaled antimicrobials: Do we get the drug to the bug?
PK/PD murine infection models: Focus on study elements, variability, and interpretation of results
Non-traditional antibacterial therapeutic options and challenges
Testing for the potential of emergence of antimicrobial resistance
Innovation in point-of-care diagnostics for sepsis and bloodstream infections
Converting Gram-positive-only compounds into broad-spectrum antibiotics
Natural product antibiotics: from traditional screening to novel discovery approaches
Models for antimicrobial R&D: Advanced and complex in vivo models for infectious disease research
Models for antimicrobial R&D: Computational modelling for population PK and PKPD
Enabling academia to fill the discovery gap – Learnings from industry and funders
Infection models for antimicrobial R&D: Intracellular models
Find out how GARDP is redoubling its efforts to accelerate the development and delivery of new and improved antibiotics.
Models for antimicrobial R&D: Development and use of in vivo models for infectious disease research
Mining Chemical Libraries for New Antibacterials
Clinical development for non-developers Part 3: Antibacterial Drug Enhancer Combinations and Non-traditional Products
NIAID Resources to Facilitate Discovery & Development of Anti-Infectives
Making Safety a Part of Drug Design
Clinical development for non-developers, part 2: Development of antibacterial drugs targeting specific pathogens
PK-PD in support of accelerated programmes for antimicrobial development: how much is enough?
Antibacterial drugs: Clinical development for non-developers Part 1: Traditional development – tiers A and B
Bacterial efflux
Minimum inhibitory concentration (MIC)
Pandrug-resistant (PDR)
Pharmacokinetics-pharmacodynamics (PK/PD)
Extensively drug-resistant (XDR)
Chemistry, manufacturing and controls (CMC)
Multidrug-resistant (MDR)